234 related articles for article (PubMed ID: 32798601)
1. Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
Patel MC; Mishin VP; De La Cruz JA; Chesnokov A; Nguyen HT; Wilson MM; Barnes J; Kondor RJG; Wentworth DE; Gubareva LV
Antiviral Res; 2020 Oct; 182():104906. PubMed ID: 32798601
[TBL] [Abstract][Full Text] [Related]
2. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
3. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
4. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions.
Koszalka P; Farrukee R; Mifsud E; Vijaykrishna D; Hurt AC
Influenza Other Respir Viruses; 2020 Jul; 14(4):460-464. PubMed ID: 32045100
[TBL] [Abstract][Full Text] [Related]
5. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
6. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
7. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
Lee LY; Zhou J; Koszalka P; Frise R; Farrukee R; Baba K; Miah S; Shishido T; Galiano M; Hashimoto T; Omoto S; Uehara T; Mifsud EJ; Collinson N; Kuhlbusch K; Clinch B; Wildum S; Barclay WS; Hurt AC
PLoS Pathog; 2021 May; 17(5):e1009527. PubMed ID: 33956888
[TBL] [Abstract][Full Text] [Related]
10. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
[TBL] [Abstract][Full Text] [Related]
11. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
12. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
[TBL] [Abstract][Full Text] [Related]
13. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
Chesnokov A; Patel MC; Mishin VP; De La Cruz JA; Lollis L; Nguyen HT; Dugan V; Wentworth DE; Gubareva LV
J Infect Dis; 2020 Jan; 221(3):367-371. PubMed ID: 31541547
[TBL] [Abstract][Full Text] [Related]
14. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.
Ince WL; Smith FB; O'Rear JJ; Thomson M
J Infect Dis; 2020 Aug; 222(6):957-961. PubMed ID: 32253432
[TBL] [Abstract][Full Text] [Related]
16. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
17. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
Hickerson BT; Adams SE; Barman S; Miller L; Lugovtsev VY; Webby RJ; Ince WL; Donnelly RP; Ilyushina NA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0000922. PubMed ID: 35262375
[TBL] [Abstract][Full Text] [Related]
19. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
Govorkova EA; Takashita E; Daniels RS; Fujisaki S; Presser LD; Patel MC; Huang W; Lackenby A; Nguyen HT; Pereyaslov D; Rattigan A; Brown SK; Samaan M; Subbarao K; Wong S; Wang D; Webby RJ; Yen HL; Zhang W; Meijer A; Gubareva LV
Antiviral Res; 2022 Apr; 200():105281. PubMed ID: 35292289
[TBL] [Abstract][Full Text] [Related]
20. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Abed Y; Saim-Mamoun A; Boivin G
Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]